Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021279 · ClinicalTrials.gov registry record · NA
ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study
A NA study, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 161
- Enrollment target
NCT02021279: Completed NA study, sponsored by Integra LifeSciences Corporation.
NCT02021279 is a NA study that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 161 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02021279, a NA study, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 161 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.
Primary Outcome
The composite outcome of surgical success evaluates anatomic outcome, patient reported outcome, and no retreatment pelvic organ prolapse.
Interventions
- DEVICE MatriStem Pelvic Floor Matrix
- PROCEDURE native tissue repair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2014-06-11 |
| Est. Completion | 2021-04-28 |
| Phase | NA |
What the finished NCT02021279 record still lists
NCT02021279 is an interventional study that assigns participants to a tested intervention. The registered 161 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which MatriStem Pelvic Floor Matrix is the first listed.
NCT02021279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02021279 about?
NCT02021279 is a clinical study titled "ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study". The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.
What is the current status of trial NCT02021279?
This trial is currently completed. It is a NA study. The enrollment target is 161 participants. The study started on 2014-06-11. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT02021279?
The interventions under investigation include: MatriStem Pelvic Floor Matrix (DEVICE), native tissue repair (PROCEDURE).
Who is sponsoring clinical trial NCT02021279?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02021279's enrollment target sits among peer trials
161 628th of 2000 higher than 1,373 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06391034 · 161 participants · Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
- NCT06546670 · 161 participants · Phase 1
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- NCT06616766 · 161 participants · Phase 1
A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
- NCT06752356 · 161 participants · Phase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI